183 related articles for article (PubMed ID: 37760587)
1. Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies.
Ucciero A; Pagnoni F; Scotti L; Pisterna A; Barone-Adesi F; Gaidano G; Patriarca A; Lunghi M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760587
[TBL] [Abstract][Full Text] [Related]
2. Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
Vachhani P; Ma E; Xu T; Montez M; Worth S; Yellow-Duke A; Cheng WH; Werner ME; Abbas J; Donnellan W
Cancer Med; 2023 Sep; 12(17):17914-17923. PubMed ID: 37568276
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
Hoff FW; Patel PA; Belli AJ; Hansen E; Foss H; Schulte M; Wang CK; Madanat YF
Leuk Lymphoma; 2023 Jun; 64(6):1123-1128. PubMed ID: 37052347
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
7. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Gershon A; Ma E; Xu T; Montez M; Naqvi K; Ku G; Cheng WW; Flahavan EM; Kota V; Greenwald DR
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e222-e231. PubMed ID: 36925388
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.
Freeman T; Williams K; Puto M; Waller A; McLaughlin EM; Blachly JS; Roddy J
World J Oncol; 2023 Feb; 14(1):40-50. PubMed ID: 36896000
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.
Chatzilygeroudi T; Darmani I; El Gkotmi N; Vryttia P; Douna S; Bouchla A; Labropoulou V; Kotsopoulou M; Symeonidis A; Pagoni M; Pappa V; Papageorgiou SG
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38276092
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Gill SI; Lai C; Porter DL; Skuli S; Bruno XJ; Carroll MP; Freyer CW; Carulli A; Babushok DV; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Loren AW; Paralkar VR; Maillard IP; Pratz KW
Am J Hematol; 2023 Aug; 98(8):1254-1264. PubMed ID: 37334852
[TBL] [Abstract][Full Text] [Related]
13. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
[TBL] [Abstract][Full Text] [Related]
17. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Pratz KW; Panayiotidis P; Recher C; Wei X; Jonas BA; Montesinos P; Ivanov V; Schuh AC; DiNardo CD; Novak J; Pejsa V; Stevens D; Yeh SP; Kim I; Turgut M; Fracchiolla N; Yamamoto K; Ofran Y; Wei AH; Bui CN; Benjamin K; Kamalakar R; Potluri J; Mendes W; Devine J; Fiedler W
Blood Cancer J; 2022 Apr; 12(4):71. PubMed ID: 35443742
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
Cancer; 2024 Mar; ():. PubMed ID: 38470375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
